These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33973231)

  • 1. Cost-Sharing Increase, Medication Adherence, and Hospitalizations in Schizophrenia Patients: A Natural Experiment.
    Serra-Burriel M; Hurtado I; Sanfélix-Gimeno G; García-Sempere A; Peiró S
    Clin Pharmacol Ther; 2021 Dec; 110(6):1490-1497. PubMed ID: 33973231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia: A Nationwide Analysis.
    Hamina A; Tanskanen A; Tiihonen J; Taipale H
    Med Care; 2020 Sep; 58(9):763-769. PubMed ID: 32732784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse clinical events among medicare beneficiaries using antipsychotic drugs: linking health insurance benefits and clinical needs.
    Fung V; Price M; Busch AB; Landrum MB; Fireman B; Nierenberg A; Dow WH; Hui R; Frank R; Newhouse JP; Hsu J
    Med Care; 2013 Jul; 51(7):614-21. PubMed ID: 23752219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic Medication Adherence and Diabetes-Related Hospitalizations Among Medicaid Recipients With Diabetes and Schizophrenia.
    Egglefield K; Cogan L; Leckman-Westin E; Finnerty M
    Psychiatr Serv; 2020 Mar; 71(3):236-242. PubMed ID: 31744428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
    Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
    Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia.
    Lang K; Federico V; Muser E; Menzin J; Menzin J
    J Med Econ; 2013 Aug; 16(8):997-1006. PubMed ID: 23777223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
    Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
    Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds.
    Frey S; Stargardt T
    Pharmacotherapy; 2012 Oct; 32(10):880-9. PubMed ID: 23033227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder.
    Broder MS; Greene M; Chang E; Hartry A; Yan T; Yermilov I
    J Med Econ; 2019 Jan; 22(1):63-70. PubMed ID: 30376745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
    Jiang Y; Ni W
    Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic prescription filling in patients with schizophrenia or schizoaffective disorder.
    Reutfors J; Brandt L; Stephansson O; Kieler H; Andersen M; Bodén R
    J Clin Psychopharmacol; 2013 Dec; 33(6):759-65. PubMed ID: 24126686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study.
    Kroken RA; Johnsen E; Ruud T; Wentzel-Larsen T; Jørgensen HA
    BMC Psychiatry; 2009 May; 9():24. PubMed ID: 19445700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial.
    Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Staring AB; Mulder CL
    Lancet Psychiatry; 2017 Mar; 4(3):199-207. PubMed ID: 28236956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of an Institutional Medication Adherence Program for Long-Acting Injectable Risperidone on Adherence and Psychiatric Hospitalizations: Evidence from a Prospective Cohort Study.
    Jalbert JJ; Rossignol M; Astruc B; Baylé F; Nordon C; Avouac B; Rouillon F; Abenhaim L; Grimaldi-Bensouda L
    J Popul Ther Clin Pharmacol; 2017 May; 24(2):e61-e70. PubMed ID: 28594483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia.
    Ascher-Svanum H; Zhu B; Faries D; Lacro JP; Dolder CR
    J Clin Psychiatry; 2006 Jul; 67(7):1114-23. PubMed ID: 16889456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
    Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM
    Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.